Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28696903 | 0.81 | KMT2A (0.42) | TRPV4CCR1RAB9ACCR5HSD11B1 | |
| SCHEMBL30540039 | 0.81 | TRPV4 (0.39) | TRPV4ALDH1A1HSD17B10TDP1GAA | |
| SCHEMBL540698 | 0.81 | TRPV4 (0.39) | TRPV4ALDH1A1HSD17B10TDP1GAA | |
| SCHEMBL26442411 | 0.80 | L3MBTL1 (0.41) | CCR1RAB9ACCR5HSD11B1ALDH1A1 | |
| SCHEMBL31717288 | 0.79 | TRPV4 (0.34) | TRPV4CCR1RAB9ACCR5HSD11B1 | |
| SCHEMBL31645084 | 0.79 | KMT2A (0.36) | TRPV4CCR1RAB9ACCR5HSD11B1 | |
| SCHEMBL25373682 | 0.79 | TRPV4 (0.34) | TRPV4ALDH1A1HSD17B10TDP1KMT2A | |
| SCHEMBL21777236 | 0.79 | TRPV4 (0.34) | TRPV4ALDH1A1HSD17B10TDP1KMT2A | |
| SCHEMBL18200089 | 0.78 | CA1 (0.39) | CCR1RAB9ACCR5ALDH1A1GAA | |
| SCHEMBL8432927 | 0.78 | MYC (0.36) | CCR1RAB9ACCR5HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161281-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2016173493-A1 | SULFONYLAMINOCARBONYL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161281-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | TRPV4 4584/4885CCR1 1453/4885RAB9A 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.